Premium
Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti‐inflammatory drugs
Author(s) -
Chand N.,
Harrison J. E.,
Rooney S. M.,
Nolan K. W.,
Vine C. L.,
Jakubicki R. G.,
Pillar J.,
Diamantis W.,
Sofia R. D.
Publication year - 1993
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1993.tb00759.x
Subject(s) - medicine , eosinophilia , bronchoalveolar lavage , methylprednisolone , immunology , dexamethasone , asthma , eosinophil , aeroallergen , pharmacology , allergy , lung , allergen
Aeroallergen‐induced infiltration of eosinophils in the bronchoalveolar lavage fluid (BALF) in guinea pigs was used as a marker of bronchial inflammation. Drugs were administered orally 4 h after aeroallergen challenge. Allergic bronchial eosinophilia in guinea pigs was inhibited by orally administered dexamethasone and methylprednisolone. Terfenadine (a newer H 1 ‐receptor antagonist), theophylline (a nonspecific phosphodiesterase inhibitor), and salbutamol (a β2‐agonist) did not influence allergic eosinophilic infiltration. Many of these agents, administered prophylactically, have been reported to suppress allergic eosinophilic infiltration in the BALF of guinea pigs. Methylprednisolone, a steroid, inhibits allergic bronchial eosinophilia regardless of the time of administration; that is, 2 h before or 4 h after aeroallergen challenge. The therapeutic approach used in this study may facilitate drug discovery for bronchial inflammation/ asthma.